Pharmaceuticals

The arrival of South Africa's first generic hormonal IUD aims to tackle high costs and low uptake of long-acting contraception in a nation of high unplanned pregnancies.

Hundreds of lupus advocates descended on Washington, demanding policy reform and research funding, and their persistent efforts are already yielding major results.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

A new state-of-the-art facility in Chicago aims to secure life-saving medicines, as GEODIS enters a heated race for pharmaceutical logistics dominance.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

Remix Therapeutics' first-in-class drug REM-422 targets a rare cancer at its genetic source, with pivotal data set for a major oncology conference.

Adocia extends its cash runway to 2027 with a new loan, but the deal could make its key investor the largest shareholder, creating a dilution dilemma.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.

Dizal to unveil late-breaking ZEGFROVY data for NSCLC, plus new findings for drugs tackling resistance and boosting immunotherapy at ASCO 2026.

The new Molecule Search platform unifies chemical and biological data, aiming to accelerate drug discovery in an increasingly competitive, AI-driven market.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

ProRx Pharma touts a major expansion to meet drug demand, but recent FDA warnings and massive recalls raise serious questions about its quality and safety.

AI promises to transform drug discovery, but billions in investment are at risk. A new report reveals why the real bottleneck isn't tech, but data itself.

Harrington Discovery Institute opens its 2027 award call, offering millions in funding and expert support to turn academic research into life-saving medicines.

A novel drug candidate from Addex Therapeutics shows robust cough suppression in key preclinical studies, offering hope for a treatment without current side effects.